• metastatic/advanced hepatocellular cancer (mHCC)
• mHCC - (neo)adjuvant (NA) 3
• mHCC - 1st line (L1) 10
• mHCC - 2nd line (L2) 2
• lung cancer : non small cell (NSCLC) 5

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus bevacizumab
• atezolizumab plus cabozantinib
• camrelizumab based treatment
• durvalumab based treatment
• durvalumab plus bevacizumab
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab plus lenvatinib
• sintilimab based treatment
• sintilimab
• Tislelizumab
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• VEGF(R) inhibitor
• bevacizumab based treatment
• bevacizumab

• versus all
• vs non active control
• vs placebo
• vs VEGF(R) inhibitor
• vs lenvatinib
• vs sorafenib

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mHCC - 1st line (L1), ... vs. VEGF(R) inhibitor, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;